Structural insights into human ABCC4 mediated transport of platelet agonist and inhibitor
暂无分享,去创建一个
Cong-Zhao Zhou | Kang-Li Xu | Qiong Li | Yuxing Chen | Zhimin Zha | W. Hou | Liang Wang | Yu Chen
[1] Cong-Zhao Zhou,et al. Structural basis of substrate recognition and translocation by human very long-chain fatty acid transporter ABCD1 , 2022, Nature Communications.
[2] R. Allikmets,et al. The human ATP‐binding cassette (ABC) transporter superfamily , 2022, Human mutation.
[3] Cong-Zhao Zhou,et al. Structures of human bile acid exporter ABCB11 reveal a transport mechanism facilitated by two tandem substrate-binding pockets , 2022, Cell Research.
[4] R. Tampé,et al. Structural and Mechanistic Principles of ABC Transporters. , 2020, Annual review of biochemistry.
[5] Jue Chen,et al. ATP Binding Enables Substrate Release from Multidrug Resistance Protein 1 , 2018, Cell.
[6] Jue Chen,et al. Structural Basis of Substrate Recognition by the Multidrug Resistance Protein MRP1 , 2017, Cell.
[7] J. Schuetz,et al. The ABCC4 membrane transporter modulates platelet aggregation. , 2015, Blood.
[8] G. Peters,et al. Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine , 2014, SpringerPlus.
[9] P. Kalinski. Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.
[10] C. Gaudio,et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. , 2011, Journal of the American College of Cardiology.
[11] G. Davı̀,et al. Platelet activation and atherothrombosis. , 2007, The New England journal of medicine.
[12] H. Kusuhara,et al. Involvement of MRP4 (ABCC4) in the Luminal Efflux of Ceftizoxime and Cefazolin in the Kidney , 2007, Molecular Pharmacology.
[13] Yuichi Sugiyama,et al. Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir , 2007, Molecular Pharmacology.
[14] Yuichi Sugiyama,et al. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. , 2007, Journal of the American Society of Nephrology : JASN.
[15] M. Huang,et al. Topotecan is a substrate for multidrug resistance associated protein 4. , 2006, Current drug metabolism.
[16] D. Keppler,et al. Prostanoid transport by multidrug resistance protein 4 (MRP4/ABCC4) localized in tissues of the human urogenital tract. , 2005, The Journal of urology.
[17] H. Kroemer,et al. The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. , 2004, Blood.
[18] J. Wijnholds,et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[19] Liqi Lai,et al. Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. , 2002, The Biochemical journal.
[20] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[21] Zhe-Sheng Chen,et al. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. , 2001, The Journal of biological chemistry.
[22] A. Tsai,et al. Substrate Binding Is the Rate-limiting Step in Thromboxane Synthase Catalysis* , 2001, The Journal of Biological Chemistry.
[23] J. Lankelma,et al. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export , 2000, British Journal of Cancer.
[24] D. Bell,et al. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. , 1998, Cancer research.
[25] M. R. Alexander,et al. Dipyridamole: A Critical Evaluation , 1984, Drug intelligence & clinical pharmacy.
[26] J. M. Lipton,et al. Analogs of endoperoxide precursors of prostaglandins: failure to affect body temperature when injected into primary and secondary central temperature controls. , 1977, Prostaglandins.
[27] J. Ambrus,et al. Critical evaluation. , 1965, The Wistar Institute symposium monograph.